NFE2L2 and cancer: In patients, activation of the NRF2 pathway is associated with more aggressive disease (Homma et al, 2009; Solis et al, 2010) and decreased response to various classes of cancer therapeutics (Gadgeel et al, 2020; Jaenne et al, 2022; Skoulidis et al, 2021).